The use of these DNMT inhibitors in pre-clinical studies has been shown to suppress tumour growth [51], and currently, DNMT inhibitors in combination with chemotherapy, AR inhibitors and immunotherapy are in clinical development for prostate cancer (Table 1). The gene discussed is DNMT1; the disease is prostate carcinoma.